“I believe that Israel has become the world’s laboratory at the moment because they only use our vaccine in this condition and have vaccinated a very large part of their population so that we can study the economic and health indices,” said Albert Bourla, CEO of Pfizer, said an interview given to NBC News on Friday.
“What we have seen is that the vaccine efficacy in the actual data is getting higher as we are talking, after the second vaccination, so seven days compared to 14 days after the second vaccination, there is a difference in efficacy,” Bourla said. assert. .
Asked if anyone else could be infected after receiving two doses of the vaccine, he said: ‘This is something that needs to be confirmed, and the real data we get from Israel and other studies will help us get it. better understand.
Bourla further noted that studies on the risk of the vaccine are also underway in pregnant women and younger children.
“We already have a license for children aged 16 and over … we are already doing trials for children between the ages of 11 and up to 16, and I hope we can have data in a few months. We also plan to to start pediatric studies from a younger age, from the age of 5 to the age of 11. And I believe we should have data on this population by the end of the year, ‘Bourla told NBC.
Bourla said that the current data show that the protection is strong after six months, but that we have to wait up to a year to determine whether it remains for the full year.
cnxps.cmd.push (function () {cnxps ({playerId: ’36af7c51-0caf-4741-9824-2c941fc6c17b’}). deliver (‘4c4d856e0e6f4e3d808bbc1715e132f6’);});
if (window.location.pathname.indexOf (“656089”)! = -1) {console.log (“hedva connatix”); document.getElementsByClassName (“divConnatix”)[0].style.display = “none”;}